Cardiac Absoludy Troponin-I
본문
Troponin is released during MI from the cytosolic pool of myocytes. Its subsequent release is prolonged with degradation of actin and myosin filaments. Measuring the level of Troponin I is to help to rule out Myocardial Infarction(MI) early. The high specificity of cTnI measurements is beneficial in identifying cardiac injury for clinical conditions involving skeletal muscle injury resulting from surgery, trauma, extensive exercise, or muscular disease.
ADVANTAGE
SPECTIFICATION
|
AMR |
10~2,000 pg/mL |
|
Test time |
5 Min |
|
Samples Type |
Serum and Plasma (Lithiumheparin and K₂-EDTA) |
|
Samples Volume |
50 uL |
|
Contact |
Cartridge_20EA |
|
Pretreatment_20EA |
|
|
Disposable Tip_24EA |
|
|
Code Chip_1EA |
|
|
Package Insert_1EA |
RESULT DATA
PROCEDURE
.
ADVANTAGE
SPECTIFICATION
|
AMR |
10~2,000 pg/mL |
|
Test time |
5 Min |
|
Samples Type |
Serum and Plasma (Lithiumheparin and K₂-EDTA) |
|
Samples Volume |
50 uL |
|
Contact |
Cartridge_20EA |
|
Pretreatment_20EA |
|
|
Disposable Tip_24EA |
|
|
Code Chip_1EA |
|
|
Package Insert_1EA |
RESULT DATA
PROCEDURE
.
